Skip to search formSkip to main contentSkip to account menu

CB-154

Known as: CB 154, CB154 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1984
1984
The effect of different schedules of bromocriptine-mesilate (CB-154; 0.2 mg/day) treatment on the development of precancerous… 
Highly Cited
1982
Highly Cited
1982
The effects of bromocryptine (CB-154) on prolactin (PRL) and luteinizing hormone (LH) secretion were studied in lactating sows… 
Highly Cited
1978
Highly Cited
1978
In 12 acromegalics a single oral dose of 0.2 mg lisuride, an ergoline derivative, significantly reduced plasma PRL but not GH… 
1978
1978
Bromocriptine produces long-lasting hypomotility and decreases brain dihydroxyphenylacetic acid (DOPAC) in mice. These effects… 
1977
1977
In an attempt to evaluate the dynamics of growth hormone (GH) and prolactin secretion in acromegalic patients, the response of… 
1977
1977
Fifteen female patients with amenorrhea and hyperprolactinemia were studied 1 to 3 times daily during the first 4 days of… 
1976
1976
In order to evaluate the importance of prolactin in the pathogenesis and clinical evolution of fibrocystic disease of the breast… 
1976
1976
The influence of 2-bromo-alpha-ergocryptine (CB-154) and 2-chloro-6-methyl-ergoline-8beta-acetonitrile methanesulfonate… 
Highly Cited
1974
Highly Cited
1974
ABSTRACT A single oral dose of the ergot alkaloid, 2-Br-a-ergocryptine (CB-154) (1.25 to 5 mg) caused a significant decrease… 
1972
1972
The effect of pituitary transplants into the anterior chamber of the eye of the rat on the amine turnover in the tubero…